Spero Therapeutics, Inc.

SPRO Nasdaq SEC CIK 1701108
Follow Spero Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $0
Net income −$44.3M −499.8% vs same quarter last year
EPS, diluted −$0.76 −484.6% vs same quarter last year
Operating cash flow −$42.6M −344.6% vs same quarter last year
Revenue by quarter
$52K
$12K
$0
$0
$12.6M
$0
$0
$0
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income12 fiscal years
  • Revenue
  • Net income
−$100M−$50M$0$50MFY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$12.6M$8.6M
FY24$371K−$68.6M
FY23$933K$22.8M
FY22$2.5M−$46.4M
FY21$3.1M−$89.8M
FY20$258K−$78.3M
FY19$4.7M−$60.9M
FY18$4M−$41.7M
FY17$2M−$38.7M
FY16$335K−$25.5M
FY15-−$10.2M
FY14--
MarginsShare of revenue
  • Operating margin
  • Net margin
−40000%−30000%−20000%−10000%0%10000%FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY2550.2%68.1%
FY24−19773.9%−18481.4%
FY232302.4%2444.4%
FY22−1685.9%−1854.4%
FY21−2865.5%−2925.1%
FY20−30664%−30348.8%
FY19−1333.1%−1284.3%
FY18−1079.3%−1051.4%
FY17−2108.6%−1957.7%
FY16−9916.7%−7609.3%
FY15--
FY14--
Free cash flowOperating cash flow minus capital expenditure
−$100M−$75M−$50M−$25M$0FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25-
FY24-
FY23-
FY22-
FY21-
FY20−$86M
FY19−$50.3M
FY18−$42.1M
FY17−$39.1M
FY16−$29.8M
FY15−$9.8M
FY14-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Spero Therapeutics
  • Healthcare median
−40000%−30000%−20000%−10000%0%10000%FY15FY17FY19FY21FY23FY25
Show the numbers
YearSpero TherapeuticsHealthcare median
FY2568.1%−30.6%
FY24−18481.4%−47%
FY232444.4%−58%
FY22−1854.4%−80.4%
FY21−2925.1%−71.8%
FY20−30348.8%−62.2%
FY19−1284.3%−46.2%
FY18−1051.4%−49.6%
FY17−1957.7%−45.9%
FY16−7609.3%−36%
FY15-−37.8%
FY14-−35.5%